The Journal of Hematopathology, published by SPRINGER HEIDELBERG, serves as a vital resource in the fields of hematology, histology, and pathology. Established in 2008, this peer-reviewed journal aims to foster the exchange of knowledge among researchers, clinicians, and students by publishing original articles, reviews, and case studies that contribute to the understanding of hematopathological disorders. While the journal currently ranks in the fourth quartile in various categories including hematology and histology, it positions itself as a platform for emergent research and insights, addressing the evolving landscape of blood-related diseases. Although not an open access journal, it provides crucial access to research findings for professionals looking to stay abreast of developments in pathologic diagnostics and therapeutic strategies. As it continues to grow, the journal remains committed to enhancing the knowledge base and scientific discourse in hematopathology.

CONGENITAL ANOMALIES is a notable journal published by WILEY, dedicated to advancing the understanding of congenital disorders and anomalies through high-quality research and clinical insights. With an ISSN of 0914-3505 and an E-ISSN of 1741-4520, this journal has been a key resource for professionals in the fields of pediatrics, embryology, and developmental biology since its inception in 1973, although coverage discontinued in Scopus after 2019 due to evolving standards in publication. The journal is ranked in the 48th percentile in the domain of pediatrics, as well as in the 26th and 14th percentiles respectively for embryology and developmental biology, placing it among respected publications in its category. Although it does not currently offer open access options, its contributions remain vital for researchers, healthcare professionals, and students seeking up-to-date information on congenital anomalies, their origins, and potential interventions. With a commitment to fostering knowledge in this critical area of health science, CONGENITAL ANOMALIES continues to play an important role in the intersection of scientific research and clinical practice.

CLINICAL DYSMORPHOLOGY, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of anatomy, genetics, and pediatric health, with a significant focus on the study of congenital disorders and their phenotypic manifestations. Established in 1992, this esteemed journal has contributed valuable insights into the understanding of dysmorphic syndromes and their clinical implications, making it an essential resource for researchers, clinicians, and students alike. With an impact factor indicative of its robust scholarly influence, CLINICAL DYSMORPHOLOGY engages a diverse readership through specialized articles, case studies, and reviews that advance the knowledge of genetic conditions and associated anatomical anomalies. Although it operates under a non-open access model, the journal is highly regarded with a 2023 ranking of Q3 in Anatomy and Q4 in several other relevant categories, reflecting its ongoing commitment to quality research in the domain of clinical medicine. Researchers and professionals are encouraged to contribute to and explore the rich content of this journal as it continues to shape the discourse in dysmorphology and related fields until its expected convergence in 2024.

Fetal and Pediatric Pathology, an esteemed journal published by TAYLOR & FRANCIS INC, is dedicated to advancing the field of pediatric and fetal medicine through the dissemination of high-quality research and clinical insights. With an ISSN of 1551-3815 and an E-ISSN of 1551-3823, the journal has been a key resource for researchers and practitioners since its inception in 1983. Based in the United Kingdom, it covers a broad spectrum of topics relevant to Medicine, Pathology and Forensic Medicine, and Pediatrics, Perinatology, and Child Health, consistently reflecting on contemporary challenges faced in these fields. The journal has attained a commendable Q3 ranking within its categories as of 2023, underlining its relevance in the academic community. Though not an open-access publication, the research presented in Fetal and Pediatric Pathology plays a pivotal role in informing practice, guiding future studies, and enhancing the understanding of diseases affecting fetuses and children. Its convergence of research throughout multiple years, continuing until 2024, marks it as a crucial platform for ongoing scientific dialogue and innovation, aimed at fostering better health outcomes for younger populations.

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

GENES CHROMOSOMES & CANCER, published by Wiley, is a premier journal in the intertwined fields of cancer research and genetics. With an ISSN of 1045-2257 and an e-ISSN of 1098-2264, this journal has been a significant outlet for innovative research since its inception in 1989, continuing through to 2024. Positioned in the Q2 quartile of both Cancer Research and Genetics categories in 2023, it reflects a strong impact in the scientific community, as evidenced by its Scopus rankings—99th in Genetics and 83rd in Cancer Research. Though it does not provide open access options, GENES CHROMOSOMES & CANCER offers valuable insights that foster collaboration and discovery among researchers, professionals, and students dedicated to understanding the genetic underpinnings of cancer. With its reputable standing, this journal is a vital resource for those aspiring to contribute meaningful advancements in cancer genetics and therapeutic interventions.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

OPHTHALMIC GENETICS is a distinguished journal published by TAYLOR & FRANCIS INC, specializing in the intersection of genetics and ophthalmology. Established in 1981, the journal has become a vital resource for researchers, clinicians, and students interested in the genetic aspects of eye diseases and disorders. Despite not being an Open Access journal, it maintains a commendable impact within the academic community, as reflected by its Q3 ranking in clinical genetics and Q2 rankings in both ophthalmology and pediatrics in 2023. With a robust focus on clinical applications, OPHTHALMIC GENETICS aims to provide a platform for innovative research and insights that drive advancements in patient care and understanding of genetic conditions affecting vision. The journal's international readership is supported by its timely publication of articles that bridge the gap between genetic research and practical ophthalmological applications.